Key Takeaways:

  • Wegovy pills are now available at 70,000+ US pharmacies for $149/month cash price ($25 with insurance)
  • This marks the first FDA-approved oral GLP-1 medication specifically for weight loss, delivering 13.6% average weight loss
  • No refrigeration needed and eliminates injection barriers, potentially expanding access for millions of Americans

After years of anticipation, the weight loss treatment landscape just shifted dramatically. Novo Nordisk officially launched the Wegovy pill in the US on Monday, marking a new chapter of obesity treatment with the first-ever GLP-1 pill for weight loss, available at over 70,000 pharmacies including CVS, Costco, and select telehealth providers like Ro, LifeMD, and Weight Watchers.

Historic FDA Approval Sets the Stage

The FDA approved Novo Nordisk's Wegovy pill (semaglutide) on December 22, 2025, marking the first oral GLP-1 available for weight loss in adults, with the added indication to reduce the risk of major adverse cardiovascular events including death, heart attack, or stroke. This approval came just two weeks before the official launch, demonstrating unprecedented speed in bringing this treatment to market.

The approval is backed by positive results from the Phase III OASIS 4 clinical trial, where oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities. The weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg.

Clinical Results Show Real-World Impact

In the pivotal OASIS 4 trial with over 300 participants, those receiving oral semaglutide 25mg once daily alongside lifestyle intervention achieved a -13.6% change from baseline in body weight compared with a -2.4% change with placebo, with 76.3% of semaglutide patients achieving at least 5% weight loss versus 31.3% on placebo.

Furthermore, one in three people experienced 20% or greater weight loss in the OASIS 4 trial, matching the effectiveness of weekly injections without the need for needles. Serious adverse events occurred less frequently with oral semaglutide than placebo (3.9% vs 8.8%), with post-hoc analyses showing improvements in glycemic control, blood pressure, and cardiovascular risk factors, including normalization of blood glucose in more than 70% of participants with prediabetes at baseline.

Pricing Makes Treatment More Accessible

The pricing structure represents a significant shift toward affordability in the GLP-1 market. Cash-paying patients can access the starting dose for $149 per month, with the 4-milligram dose also available for $149 per month through April 15, then $199 per month after that, making these among the lowest cash prices on the market, ranging from $149 to $299 per month depending on the dose.

Patients with insurance coverage for the drug can pay as little as $25 per month for the treatment, representing a dramatic cost reduction compared to traditional GLP-1 injections. This pricing strategy directly addresses one of the biggest barriers to GLP-1 access that has prevented millions from starting treatment.

Eliminating Treatment Barriers Beyond Cost

The oral formulation addresses multiple access barriers that have limited GLP-1 adoption. Injectable forms of Wegovy must be stored in a refrigerator between 36 and 46 degrees Fahrenheit, while pill forms of Wegovy don't require refrigeration. This eliminates cold chain logistics that have complicated prescription fulfillment and travel for patients.

Novo is hoping that the new oral formulation will expand Wegovy access by introducing the drug to people with an aversion to needles and by eliminating other constraints like the need for a cold chain and refrigeration. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs.

However, the oral version does come with specific requirements. The Wegovy pill must be taken with a sip of water in the morning on an empty stomach, with a 30-minute break before eating or drinking, as people who take Novo Nordisk's pill have to wait 30 minutes before eating or drinking each day.

Competition Heats Up in Oral GLP-1 Space

The FDA's approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill, as Lilly's oral drug, orforglipron, is still under review. Rival Eli Lilly is developing orforglipron, which is expected to be approved by the FDA by summer and will also be available for the $149 starting price under the Trump agreement, with additional doses costing up to $399 for cash-paying patients.

By contrast, Lilly's orforglipron has no dosing restrictions, with clinical trials showing it was taken once a day at any time, without restrictions on food or water, potentially offering greater convenience.

What This Means for You

This launch represents the most significant advancement in GLP-1 accessibility since these medications first arrived on the market. If you've been considering weight loss treatment but were deterred by injections, refrigeration requirements, or cost, the Wegovy pill addresses all three barriers simultaneously.

The $149 monthly cash price for starting doses puts effective weight loss treatment within reach of many more Americans. For those with insurance coverage, the potential $25 copay makes this one of the most affordable prescription weight loss options available. If you're exploring your options, you can compare costs across different GLP-1 medications and find a clinic near you that prescribes the new oral formulation.

Sources: